Aim. To predict platelet accumulation around stent struts in the presence or absence of tissue defects around them. Methods. Computer simulations were performed using virtual platelets implementing the function of the three membrane proteins: glycoprotein (GP) Ibα, GPIIb/IIIa, and GPVI. These platelets were perfused around the stent struts implanted into the vessel wall in the presence or absence of tissue defects around them using within the simulation platform. The number of platelets that adhered around stent struts was calculated by solving the blood flow using Navier–Stokes equation along with the adhesion of membrane protein modeled within the platform. Results. Platelet accumulation around stent struts occurred mostly at the downstream region of the stent strut array. The majority of platelets adhered at the downstream of the first bend regardless of the tissue defect status. Platelet adhesion around stent struts occurred more rapidly in the presence of tissue defects. Conclusion. Computer simulation using virtual platelets suggested a higher rate of platelet adhesion in the presence of tissue defects around stent struts.

1. Introduction

Coronary stent implantation is a common procedure for treating patients with acute and chronic coronary artery diseases [1–3]. Indeed, stent implantation is effective for preventing acute phase coronary occlusion by restoration of normal anatomy [4]. Stent thrombosis occurring in the subacute phase is managed well with appropriate antiplatelet therapy [5]. Antiplatelet therapy helps to maintain the arterial lumen, and thus, it also facilitates maintenance/restoration of normal anatomy. Recently, drug-eluting stents (DES) using sirolimus [6, 7], paclitaxel [8, 9], or zotarolimus [10] have been shown to prevent restenosis by inhibiting smooth muscle growth [11]. Drug-eluting stents were proven to be effective in reducing the need for target vessel revascularization in patients at high risk for restenosis without a significant increase in the risk of myocardial infarction or death [12].

Due to the reduced risk of thrombotic complication with recent stents, the more recent recommended length for strong antiplatelet therapy using the combination of aspirin and P2Y12 inhibitors has been shortened [13–15]. In general, the risk of thrombotic events is no longer higher than the risk of serious bleeding complication caused by dual antiplatelet therapy several months after DES implantation [16]. Stent thrombosis in late term is rare but is an event that can lead to severe, negative patient outcomes including death [17, 18]. However, it is suggested that risk stratification based on various conditions can be helpful to identify patients who require extended antiplatelet therapy [19]. Risk stratification demonstrates that there is a higher risk of late phase stent thrombosis in patients with malapposition of stents [20–24]. Thus, it may be reasonable to consider longer DAPT duration for patients with stent malapposition. However, extending DAPT duration is associated with a higher risk of serious bleeding complication [25, 26]. Thus, further studies
are needed to develop safer treatment strategies that specifically target patients with stent malapposition.

The mechanism of an increased risk of stent thrombosis in patients with stent malapposition is not understood [23, 27]. This lack of understanding creates a barrier for developing new treatment protocols. In patients with drug-eluting stents, stent malapposition was associated with tissue defects around stent struts due to delayed tissue repair [28]. This has been suggested to be the result of drugs inhibiting cell proliferation [26] and could be contributing to high thrombosis rate [22]. From these findings, the present hypothesis was that tissue defects around stents caused by malapposition are contributing to the high rate of thrombosis by increasing the rate of platelet adhesion to the vessel wall.

Recent advances in the calculation power of computer and information technology facilitates in silico analysis by constructing various complicated biological phenomena such as thrombus formation by solving basic physical/chemical equations [27, 29, 30]. Using this technology, computer simulation models of platelets adhesion under various blood flow conditions were developed [29]. In this study, these computer simulations are applied to examine the contribution of tissue defects around the stent struts on the rate of platelet adhesion.

2. Method

2.1. Virtual Platelet. Virtual platelets implementing the function of adhesion at site of endothelial injury, activation, and aggregation were used in this study. The details of virtual platelets have been published previously [29]. The function of three major platelet membrane proteins, namely, glycoprotein (GP) Ibα, GPIIb/IIIa, and GPVI, was integrated into the virtual platelet, computer simulation as in the Kelvin–Voigt model [29]. Virtual platelets adhere at the region of virtual endothelial injury mimicking the function of GP Ibα interacting with the von Willebrand factor (VWF) and collagen fibrils exposed to the blood stream [29]. The outside-in signaling caused by stimulations of GPVI (by collagen) [31], GPIIbα (by VWF) [31], and other chemical receptors on platelets (by various soluble agents such as adenosine 5’-diphosphate (ADP) [32], epinephrine [33], and thrombin [34]) were modeled by the activation of virtual platelet upon adhesion to the vessel wall. To model the firm adhesion caused by platelet activation, the binding constant was increased upon platelet adhesion on VWF/collagen as published previously [29]. The validity of the abovementioned virtual platelet model was confirmed by extended computer simulation implementing the local activation of coagulant cascade on activated platelets [30]. Biological validity of the virtual platelets used in this study was confirmed by experiments using human blood specimens and parallel plate flow chambers [31–36].

2.2. Solving Blood Flow around Stent Struts. Blood flow around stent struts were calculated by solving the discretized Navier–Stokes equation [27, 29, 30]. Briefly, the diameter of the target vessel was set to 3 mm. Blood flow was simulated as pulsatile flow with a linear change in blood flow from 0 to 22.5 mm/sec. The initial density of platelets in blood was set to \(300 \times 10^6/ml\) and distributed uniformly. The \(\Delta t\) for calculation was defined as 0.01 second.

The stents are implanted as shown in Figure 1(a). Stent struts were implanted into the vessel wall as shown in Figure 1(b). The stent strut has a round shape with a diameter of 0.09144 mm. Half of the diameter of stent struts was buried in the vessel wall, but the other half was exposed to the blood stream. The initial direction of blood flow was set to be parallel to \(y\)-direction (\(x\)- and \(z\)-axis components were 0).

2.3. Tissue Defect around Stent Strut. Tissue defects are organized around the stent struts as illustrated in Figure 2. The sizes of tissue defects were equal to the diameter of stent struts (Figure 2(c)).

2.4. Conditions for the Simulation. Virtual blood with the density of 1,000 kg/m\(^3\) and dynamic kinematic viscosity coefficient of 0.001004 m\(^2\)/s was perfused for 30 seconds in the virtual vessel with the diameter of 3 mm and in the presence of stent struts with or without tissue defects. The number of virtual platelets adhering around stent struts was calculated with a high-performance computer equipped with an Intel® Xeon Phi\textsuperscript{TM} 7210 processor (Intel Corporation, Santa Clara, CA, USA). The distribution of platelet adhesion at 1-, 3-, and 10-second perfusion of virtual blood is shown in both conditions in the presence and absence of tissue defect around stents. Time-dependent changes in the number of platelets adhering to the area around stent struts were calculated. Calculated results are also shown as supplemental movies.

3. Results

3.1. Blood Flow toward the Vessel Wall Was Observed Downstream of Stent Strut. Although the initial \(z\)-axis component of blood flow velocity was 0, flow in the \(z\)-axis direction was observed when the blood flow reached the stent struts. The distributions of \(z\)-axis components of blood flow around stents at maximum velocity (mm/sec) in the absence and presence of tissue defect are shown in Figures 3(a) and 3(b), respectively. \(Z\)-axis direction velocity toward the vessel wall was higher downstream than upstream of stent strut.

3.2. Platelet Adhesion Was Pronounced around the First Stent Struts Compared to the Second Strut. Figure 4 shows the snapshots of three-dimensional (3D) projection view delineating platelet adhesion around stents in the presence and absence of tissue defects. Almost no platelets adhered around the stents at 1 second both in the presence and absence of tissue defect. Adhered platelets increased in a time-dependent manner from 3 to 10 seconds. Despite similarly higher velocity of \(z\)-axis
blood flow toward the vessel wall in the downstream of stent struts (Figure 3), more platelet adhesions were observed at downstream of the first stent strut as compared to the second at 3 seconds. The difference was larger in the absence of tissue defects (Figure 4(a)) as compared to the condition with tissue defects.
At 10 seconds, more platelet adhesion was observed in the presence of tissue defects compared with no tissue defects. Although the platelet adhesion was increased with tissue defects in downstream of both the first and second stent struts, the difference was larger around the second stent strut than the first. Full movie demonstrating the time-dependent changes in the number of platelets adhered around stent strut in the presence of tissue defect around stent struts.
presence and absence of tissue defect is provided as supplementary materials (Movies A and B).

3.3. Platelet Adhesion Was Increased with the Presence of Tissue Defect. Figure 5 shows the time-dependent increase in the number of platelets adhered in the simulation area shown as XY plane in Figure 3 from 0 to 30 seconds. Indeed, the number of adhered platelets was higher in the presence of tissue defects than that in their absence. At 30 seconds, it reached to 490/mm² in the absence of tissue defects and reached 3420/mm² in its presence.

4. Discussion

Supporting initial hypothesis, the computer simulation suggested higher rate of platelet adhesion around stent struts implanted into the vessel wall in the presence of tissue defects around them as compared to absence tissue defects. This difference is likely due to the changes in the distribution of z-axis component of platelet motions induced by the presence of stent struts because the z-axis direction velocity of blood flow toward the vessel wall was apparently higher downstream than upstream of stent struts. This was further supported by the finding that the z-axis direction velocity at downstream of stent strut in the presence of tissue defects was higher as compared to that without defects.

The results of the present research suggest that actual platelet adhesion is not fully determined by the z-axis velocity of blood flow. Indeed, apparently, more platelet adhesion was observed downstream of the first stent strut than the second strut at 3 and 10 seconds of blood perfusion regardless of the presence of tissue defects. The reason for this difference is not fully understood. Reduced platelet density around the second stent strut caused by the consumption of platelet by adhesion around the first stent strut is one potential explanation. However, platelet adhesion was increased with tissue defects regardless of the locations and thus supports the conclusion that tissue defects may be an important contributor for higher rate of stent thrombosis in patients with late malapposition.

Potential factors influencing the risk of late stent thrombosis are summarized in Table 1 [37–39]. General factors such as thrombogenicities exerted by platelet reactivity are managed by the appropriate use of dual antiplatelet therapy [40]. Local factors such as the thrombogenicity of the stent struts were also improved by using less thrombogenic materials and shapes [36]. A critical issue, especially for the late stent thrombosis with the use of drug-eluting stents, is the malapposition [20]. Stent malapposition or incomplete stent apposition is a morphological description defined by the lack of contact between at least one stent strut and the underlying intimal surface of the arterial wall in a segment not overlying a side branch. Clinical observations suggest a higher prevalence of tissue defects around stents causing late stent malapposition in patients experiencing late stent thrombosis [23, 24, 26, 41, 42]. However, it is important to note that the prevalence of stent malapposition differs substantially with the use of different diagnostic devices and studies. Even with the use of intravascular ultrasound (IVUS), the prevalence of late stent-malposition ranges significantly between studies from the lowest of 0% at 8 months [43] to 25% at 9 months [44]. Other studies using optical coherence tomography (OCT) report high prevalence of acute stent malapposition in 62% of the lesions treated, and 31% of them remained as malappositions at 6 months [42]. New onset of late acquired malapposition was observed in 15% of the lesions [42]. These reports suggest that imaging devices cannot completely eliminate stent malappositions.

In general, late stent malapposition is recognized as a risk factor for stent thrombosis. But, a recent report by Im et al. also demonstrated that none of the 351 patients experienced clinical stent thrombosis within 8.6 ± 10.3 months of follow-up. Meta-analysis showed higher risk of late malapposition as compared to the bare metal stent with an odds ratio of 2.49 (CI 95% 1.15–5.35) [26]. Thus, stent malapposition is one of the risk factors for stent thrombosis, but the majority of late acquired stent malapposition remains asymptomatic. The results of the present investigation show a higher rate of platelet adhesion around stent struts in the presence of tissue defects in comparison with its absence. These results do not contradict clinical findings because the accumulation of platelets is one of the triggers for thrombus formation, but contributions from other factors such as local
activation of coagulant factor is necessary to cause symptomatic coronary thrombosis [45].

Higher rate of platelet accumulation downstream of stent struts has been previously documented with human blood and flow chamber experiments [36]. This computer simulation finding is in good agreement with these previous biological, experimental findings. Detailed clinical observations with the use of OCT in patients with very late stent thrombosis revealed the presence of in-stent neointimal rupture in approximately 70% of patients [46]. The rate of neointimal rupture was higher than the prevalence of stent malapposition of 42% [46]. The contributing role of platelets in neointimal plaque formation remains to be elucidated [47, 48]. The higher rate of platelet accumulation shown here may suggest a contributing role of accumulated platelets for neointimal formation and future rupture.

4.1. Limitations. This study has several limitations as listed below.

(i) Predictive calculation in this simulation was conducted only for 30 seconds. It is likely that longer times are required for the process of stent thrombosis to be complete. Thus, the present results should be interpreted as predictive of only the initial part of the clinical phenomena, which might not necessarily result in clinically significant events such as stent thrombosis.

(ii) The clinical thrombosis often appears as sudden cardiac death or ST-elevation myocardial infarction, which is likely to be caused by arterial occlusive thrombi including both platelet and fibrin [3, 49]. This simulation only predicted early platelet accumulation but did not include the process of coagulation cascade leading to fibrin formation.

(iii) This simulation only included tissue defect around stent struts as a parameter but not others such as old age and renal dysfunction. Personalized prediction inclusive of these factors on the influence of stent thrombosis achieved may be understood by future studies.

(iv) The interaction between platelets and erythrocytes should play a role for determining the motion of platelets. This factor was not included in the current analysis. Future studies examining this aspect are now being designed in this laboratory.

4.2. Fundamental Strengths of Simulation Calculation Are the Following. The numbers of platelets accumulated around stent could be quantitatively calculated from the basic physical principals.

5. Conclusion

In conclusion, higher rate of platelet adhesion around stent struts in the presence of tissue defects as compared with its absence is shown in this computer simulation study. This study results support the notion that higher rate of platelet adhesion in the presence of tissue defects is a risk factor for stent thrombosis. Computer simulation provides insight into the higher risk of stent thrombosis in patients with stent malapposition.

Abbreviations

DES: Drug-eluting stent
GP: Glycoprotein
IVUS: Intravascular ultrasound
OCT: Optical coherence tomography
PCI: Percutaneous coronary intervention
VWF: von Willebrand factor.

Data Availability

The results of this study are generated by simulation calculation.

Conflicts of Interest

Shinya Goto acknowledge a grant-in-aid from MEXT/JSPS KAKENHI (19H03661), AMED (A368TS), Bristol-Myers Squibb for independent research support project (33999603) and a grant from Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering and Vehicle Racing Commemorative Foundation. Shinya Goto also discloses grant support from Sanofi, Pfizer, and Bristol Myer Squibb and Ono Pharma.

Supplementary Materials

Movies demonstrating the platelet adhesion in the presence and absence of tissue defect. Movie A and movie B demonstrate the platelet adhesion in the presence and absence of tissue defect around stent struts, respectively. The size and direction of each image is the same as Figure 4. (Supplementary Materials)

References

[1] G. N. Levine, E. R. Bates, J. A. Bittl et al., “2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease,” Circulation, vol. 134, no. 10, pp. e123–e155, 2016.

[2] M. Valgimigli, H. Bueno, R. A. Byrne et al., “2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS,” European Journal of Cardio-Thoracic Surgery, vol. 53, no. 1, pp. 34–78, 2017.

[3] B. Vogel, B. E. Claessen, S. V. Arnold et al., “ST-segment elevation myocardial infarction,” Nature Reviews Disease Primers, vol. 5, pp. 1–20, 2019.

[4] U. Sigwart, J. Puel, V. Mirkovitch, F. Joffre, and L. Kappenberger, "Intravascular stents to prevent occlusion and re-stenosis after transluminal angioplasty," New England Journal of Medicine, vol. 316, no. 12, pp. 701–706, 1987.

[5] M. B. Leon, D. S. Baim, J. J. Popma et al., "A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting," New England Journal of Medicine, vol. 339, no. 23, pp. 1665–1671, 1998.
[6] C. Spaulding, J. Daemen, E. Boersma, D. E. Cutlip, and P. W. Serruys, "A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents," *New England Journal of Medicine*, vol. 356, no. 10, pp. 989–997, 2007.

[7] M.-C. Morice, P. W. Serruys, J. E. Sousa et al., "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization," *New England Journal of Medicine*, vol. 346, no. 23, pp. 1773–1780, 2002.

[8] S. Windecker, A. Remondini, F. R. Eberli et al., "Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization," *New England Journal of Medicine*, vol. 353, no. 7, pp. 653–662, 2005.

[9] A. Kastrati, J. Mehilli, N von Beckerath et al., "Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial," *JAMA*, vol. 293, no. 2, pp. 165–171, 2005.

[10] P. K. Bundhun, C. M. Yanamala, and W. Q. Huang, "Comparing stent thrombosis associated with zotarolimus eluting stents versus everolimus eluting stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials," *BMC Cardiovascular Disorders*, vol. 17, p. 84, 2017.

[11] P. W. Serruys, S. Silber, S. Garg et al., "Comparison of zotarolimus-eluting and everolimus-eluting coronary stents," *New England Journal of Medicine*, vol. 363, no. 2, pp. 136–146, 2010.

[12] J. V. Tu, J. Bowen, M. Chiu et al., "Effectiveness and safety of drug-eluting stents in Ontario," *New England Journal of Medicine*, vol. 357, no. 14, pp. 1393–1402, 2007.

[13] G. El-Hayek, F. Messerli, S. Bangalore et al., "Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents," *The American Journal of Cardiology*, vol. 114, no. 2, pp. 236–242, 2014.

[14] H. Watanabe, T. Domez, T. Morimoto et al., "Very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk," *Circulation*, vol. 140, no. 23, pp. 1957–1959, 2019.

[15] L. Mauri, D. J. Kereiakes, R. W. Yeh et al., "Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents," *New England Journal of Medicine*, vol. 371, no. 23, pp. 2155–2166, 2014.

[16] P. A. Villalbancisa, D. Massera, V. Mathew et al., "Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: a meta-analysis and meta-regression," *Medicine (Baltimore)*, vol. 95, Article ID e5819, 2016.

[17] M. Ali and K. McDonald, "Very late bare-metal stent thrombosis, rare but stormy!", *Journal of Invasive Cardiology*, vol. 23, pp. E208–E210, 2011.

[18] P. Garg and L. Mauri, "The conundrum of late and very late stent thrombosis following drug-eluting stent implantation," *Current Opinion in Cardiology*, vol. 22, no. 6, pp. 565–571, 2007.

[19] S.-J. Kang, C. W. Lee, H. Song et al., "OCT analysis in patients with very late stent thrombosis," *JACC: Cardiovascular Imaging*, vol. 6, no. 6, pp. 695–703, 2013.

[20] S. Cook, P. Wenaweser, M. Togni et al., "Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation," *Circulation*, vol. 115, no. 18, pp. 2426–2434, 2007.

[21] Y. Ozaki, M. Okumura, T. F. Ismail et al., "The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study," *European Heart Journal*, vol. 31, no. 12, pp. 1470–1476, 2010.

[22] F. Zhang, J. Qian, and J. Ge, "Very late stent thrombosis in late stent malapposition after sirolimus-eluting stent implantation," *International Heart Journal*, vol. 48, no. 5, pp. 591–596, 2007.

[23] T. Sawada, J. Shite, T. Shinke et al., "Very late thrombosis of sirolimus-eluting stent due to late malapposition: serial observations with optical coherence tomography," *Journal of Cardiology*, vol. 52, no. 3, pp. 290–295, 2008.

[24] M. Taniwaki, M. D. Radu, S. Zaugg et al., "Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography," *Circulation*, vol. 133, no. 7, pp. 650–660, 2016.

[25] M. P. Bonaca, D. L. Bhatt, M. Cohen et al., "Long-term use of ticagrelor in patients with prior myocardial infarction," *New England Journal of Medicine*, vol. 372, no. 19, pp. 1791–1800, 2015.

[26] A. K. M. Hassan, S. C. Bergheau, T. Stijnen et al., "Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis," *European Heart Journal*, vol. 31, no. 10, pp. 1172–1180, 2010.

[27] S. Goto, N. Tamura, K. Ayabe et al., "A method and preliminary results of in silico computer simulation for the formation of mix thrombi with platelet and fibrin," *Journal of Biotherapy*, vol. 31, no. 2, pp. 30–34, 2017.

[28] M.-K. Hong, G. S. Mintz, C. W. Lee et al., "Late stent mal-apposition after drug-eluting stent implantation," *Circulation*, vol. 113, no. 3, pp. 414–419, 2006.

[29] A. Tomita, N. Tamura, Y. Nanazawa, S. Shiozaki, and S. Goto, "Development of virtual platelets implementing the functions of three platelet membrane proteins with different adhesive characteristics," *Journal of Atherosclerosis and Thrombosis*, vol. 22, no. 2, pp. 201–210, 2015.

[30] K. Ayabe, S. Goto, H. Oka et al., "Potential different impact of inhibition of thrombin function and thrombin generation rate for the growth of thrombi formed at site of endothelial injury under blood flow condition," *Thrombosis Research*, vol. 179, pp. 121–127, 2019.

[31] S. Goto, N. Tamura, S. Handa, M. Arai, K. Kodama, and H. Takayama, "Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions," *Circulation*, vol. 106, no. 2, pp. 266–272, 2002.

[32] S. Goto, N. Tamura, K. Eto, Y. Ikeda, and S. Handa, "Functional significance of adenosine 5′-diphosphate receptor (P2Y12) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibo induced by conditions of high shear rate," *Circulation*, vol. 105, no. 21, pp. 2531–2536, 2002.

[33] S. Goto, Y. Ikeda, M. Murata et al., "Epinephrine augments von Willebrand factor-dependent shear-induced platelet aggregation," *Circulation*, vol. 86, no. 6, pp. 1859–1863, 1992.

[34] N. Tamura, I. Kitajima, Y. Kawamura et al., "Important regulatory role of activated platelet-derived procagulant activity in the propagation of thrombi formed under arterial blood flow conditions," *Circulation Journal*, vol. 73, no. 3, pp. 540–548, 2009.

[35] S. Goto, Y. Ikeda, E. Saltivar, and Z. M. Ruggeri, "Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions," *Journal of Clinical Investigation*, vol. 101, no. 2, pp. 479–486, 1998.
[36] M. Sakakibara, S. Goto, K. Eto, N. Tamura, T. Isshiki, and S. Handa, “Application of ex vivo flow chamber system for assessment of stent thrombosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 8, pp. 1360–1364, 2002.

[37] D.-W. Park, S.-W. Park, K.-H. Park et al., “Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up,” The American Journal of Cardiology, vol. 98, no. 3, pp. 352–356, 2006.

[38] W. JWv, A. A. Heestermans, A. C Zomer et al., “Predictors of coronary stent thrombosis,” Journal of the American College of Cardiology, vol. 53, pp. 1399–1409, 2009.

[39] G. L. Buchanan, S. Basavarajaiah, and A. Chieffo, “Stent thrombosis: incidence, predictors and new technologies,” Thrombosis, vol. 2012, Article ID 956962, 2012.

[40] F. Costa and M. Valgimigli, “Long-term use of ticagrelor in patients with prior myocardial infarction,” New England Journal of Medicine NEJM, vol. 373, pp. 1271-1272, 2015.

[41] N. Foin, S. Lu, J. Ng et al., “Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model,” EuroIntervention, vol. 13, no. 9, pp. e1096–e1098, 2017.

[42] E. Im, B.-K. Kim, Y.-G. Ko et al., “Incidences, predictors, and clinical outcomes of acute and late stent malapposition detected by optical coherence tomography after drug-eluting stent implantation,” Circulation: Cardiovascular Interventions, vol. 7, no. 1, pp. 88–96, 2014.

[43] J. Fajadet, W. Wijns, G.-J. Laarman et al., “Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions,” Circulation, vol. 114, no. 8, pp. 798–806, 2006.

[44] B. L. Van Der Hoeven, S.-S. Liem, J. Dijkstra et al., “Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction,” JACC: Cardiovascular Interventions, vol. 1, no. 2, pp. 192–201, 2008.

[45] S. Goto, “Propagation of arterial thrombi,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 12, pp. 2207-2208, 2004.

[46] H. Tang, Q. Wang, X. Wang et al., “Effect of a novel stent on re-endothelialization, platelet adhesion, and neointimal formation,” Journal of Atherosclerosis and Thrombosis, vol. 23, no. 1, Article ID 31062, 2016.

[47] A. Schober, D. Manka, P. Von Hundelshausen et al., “Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury,” Circulation, vol. 106, no. 12, pp. 1523–1529, 2002.

[48] A. Schober, A. Zernecke, E. A. Liehn et al., “Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets,” Circulation Research, vol. 95, no. 11, pp. 1125–1133, 2004.

[49] Y. Hoshiba, K. Hatakeyama, T. Tanabe, Y. Asada, and S. Goto, “Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction,” Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 114–120, 2006.